HKU Scholars Hub: Browsing DSpace

Browsing by Author Gane, E

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 33 to 52 of 72 < previous next >

Title	Author(s)	Issue Date	Views
Optimal virologic and clinical efficacy at one year is associated with maximal early HBV suppression in nucleoside-treated hepatitis B patients Proceeding/Conference:Journal of Hepatology	Zeuzem, S Lai, CL Gane, E Liaw, YF Thongsawat, S Wang, YM Chen, Y Heathcote, J Rasenack, J Bzowej, N Naoumov, N Chao, G Fielman, B Brown, N	2006	147
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B Journal:New England Journal of Medicine	Lau, GK Piratvisuth, T Luo, KX Marcellin, P Thongsawat, S Cooksley, G Gane, E Fried, MW Chow, WC Paik, SW Chang, WY Berg, T Flisiak, R McCloud, P Pluck, N	2005	151
Phase III comparison of telbivudine vs lamivudine in HBeAg-positive patients with chronic hepatitis B: Efficacy, safety, and predictors of response at 1 year Proceeding/Conference:Journal of Hepatology	Gane, E Lai, CL Liaw, YF Thongsawat, S Wang, YM Cheng, Y Heathcote, J Rasenack, J Bzowej, N Naoumov, N Chao, G Fielman, B Brown, N	2006
Phase III Comparison of Telbivudine vs Lamivudine in Patients with Chronic Hepatitis B: Efficacy, Safety, and Predictors of Response at 1 Year Proceeding/Conference:Gastroenterology	Bzowej, N Lai, CL Gane, E Liaw, Y Thongsawat, S Wang, Y Chen, Y Heathcote, J Rasenack, J Naoumov, N Chao, G Fielman, B Brown, N	2006	124
Practical Difficulties in the Management of Hepatitis B in the Asia-Pacific Region Journal:Journal of Gastroenterology and Hepatology	Mohamed, R Desmond, P Suh, DJ Amarapurkar, D Gane, E Guangbi, Y Hou, JL Jafri, W Lai, CL Lee, CH Lee, SD Lim, SG Guan, R Phiet, PH Piratvisuth, T Sollano, J Wu, JC	2004	186
Preliminary on-treatment data from a phase 2 study evaluating VIR-2218 in combination with pegylated interferon alfa-2a in participants with chronic hepatitis B infection Proceeding/Conference:Journal of Hepatology	Yuen, RMF Lim, YS Cloutier, D Shen, L Arizpe, A Pang, P Tay, C Thanawala, V Gupta, SV Cathcart, A Gane, E	2021
Preliminary results from a phase 2 study evaluating VIR-2218 alone and in combination with pegylated interferon alfa-2a in participants with chronic hepatitis B infection Proceeding/Conference:APASL 2022, Seoul, Korea, 30 Mar - 3 Apr 2022. Hepatology International	Yuen, RMF Lim, Y-S Cloutier, D Thanawala, V Shen, L Arizpe, A Tay, C Gupta, SV Cathcart, AL Hwang, C Gane, E	2022
Preliminary results of a Phase 2 study of VIR-2218, an X-targeting RNAi therapeutic, in patients with chronic hepatitis B: sub-analyses of HBeAg-negative and HBeAg-positive patients Proceeding/Conference:Hepatology International	Yuen, RMF Lim, YS Cloutier, D Shen, L Cathcart, A Ding, X Arizpe, A Pang, P Huang, S Gane, E	2021	15
Preliminary safety and antiviral activity of VIR-2218, an X-targeting HBV RNAi therapeutic, in chronic hepatitis B patients Proceeding/Conference:Journal of Hepatology	Gane, E Lim, YS Tangkijvanich, P O'Beirne, J Lim, TH Bakardjiev, A Ding, X Connolly, L Huang, S Kim, J Pang, P Yuen, RMF	2020	144
Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine Journal:Clinical Gastroenterology and Hepatology	Park, J Le, AK Tseng, TC Yeh, ML Jun, DW Trinh, H Wong, GLH Cheng, CH Peng, CY Kim, SE Oh, H Kwak, MS Cheung, KSM Toyoda, H Hsu, YC Jeong, JY Yoon, EL Ungtrakul, T Zhang, J Xie, Q Ahn, SB Enomoto, M Shim, JJ Cunningham, C Jeong, SW Cho, YK Ogawa, E Huang, R Lee, DH Takahashi, H Tsai, PC Huang, CF Dai, CY Tseng, CH Yasuda, S Kozuka, R Li, J Wong, C Wong, CC Zhao, C Hoang, J Eguchi, Y Wu, C Tanaka, Y Gane, E Tanwandee, T Cheung, R Yuen, RMF Lee, HS Yu, ML Kao, JH Yang, HI Nguyen, MH	2021	14
Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in pooled data from globe and 015 studies in chronic hepatitis B patients Proceeding/Conference:Journal of Hepatology	Hsu, CW Chen, YC Liaw, YF Gane, E Manns, M Zeuzem, S Wang, Y Lai, CL Hou, J Leung, N Bzowej, N Niu, J Jia, J Hwang, SG Cakaloglu, Y Ren, H Papatheodoridis, G Chen, Y Bao, W Lopez, P	2009	126
Reduction in Hepatitis B Viral DNA and Hepatitis B Surface Antigen Following Administration of a Single Dose of VIR-3434, an Investigational Neutralizing Monoclonal Antibody: First Experience in a Population With Viremia Proceeding/Conference:The Liver Meeting 2022: American Association for the Study of Liver Diseases (AASLD) (04/11/2022-08/11/2022, Washington, USA)	Agarwal, K Yuen, MF Wedemeyer, H Cloutier, D Shen, L Arizpe, A Gupta, SV Fanget, M Seu, L Cathcart, AL Lau, AH Hwang, C Gane, E	31-Oct-2022
Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression Proceeding/Conference:Journal of Hepatology	Yuen, RMF Berliba, E Sukeepaisarnjaroen, W Strasser, S Tangkijvanich, P Holmes, J Leerapun, A Jucov, A Thi, EP Wattamwar, T Sofia, MJ Sevinsky, H Gray, K Antoniello, D Eley, T Picchio, G Sims, K Gane, E	2021	14
Reply Journal:Hepatology	Wat, C Gane, E Yuen, RMF Pavlovic, V Mueller, H Krippendorff, B-F Grippo, JF Ottosen, S	2022
Resistance monitoring data from treatment-naïve chronic HBV infected patients treated for 28 days with a new class a core protein allosteric modulator RO7049389 monotherapy Proceeding/Conference:Journal of Hepatology	Zhou, X Kazma, R Meinel, D Zhou, Y Yuen, RMF Gane, E Schwabe, C Tanwandee, T Cao, L Zhou, J Bo, Q	2020	28
RO7049389, a core protein allosteric modulator, demonstrates robust anti-HBVactivity in chronic hepatitis B patients and is safe and well tolerated Proceeding/Conference:Journal of Hepatology	Gane, E Liu, A Yuen, RMF Schwabe, C Bo, Q Das, S Goa, L Zhou, X Wang, Y Coakley, E Jin, Y	2018	91
RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients Proceeding/Conference:Journal of Hepatology	Gane, E Yuen, RMF Bo, QY Schwabe, .C Tanwandee, T Das, S Jin, YY Guo, L Zhou, X Wang, YF Feng, S Meinel, D Zhu, MF	2019
RO7049389, a core protein allosteric modulator, is safe and well tolerated in healthy volunteers and demonstrates potent anti-HBV activity in a phase 1 trial Proceeding/Conference:Journal of Viral Hepatitis	Gane, E Liu, A Yuen, RMF Schwabe, C Bo, Q Das, SB Goa, L Zhou, X Wang, Y Coakley, E Jin, Y	2018
RO7062931 antisense oligonucleotide phase 1 study demonstrates target engagement in patients with chronic hepatitis B on established nucleos(t)ide therapy Proceeding/Conference:Journal of Hepatology	Yuen, RMF Gane, E Kim, DJ Chan, H Surujbally, B Pavlovic, V Triyatni, M Grippo, J Kim, HJ Leerapun, A Lim, TH Lim, YS Tanwandee, T Kim, W Cheng, W Hu, TH Wat, C	2020
Safety and antiviral activity of VIR-2218, an X-targeting RNAi therapeutic, in participants with chronic hepatitis B infection: week 48 follow-up results Proceeding/Conference:Journal of Hepatology	Gane, E Lim, YS Cloutier, D Shen, L Cathcart, A Ding, X Pang, P Huang, S Yuen, RMF	2021

Showing results 33 to 52 of 72 < previous next >